Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 345 full-time employees. The firm is engaged in creating and delivering advancements in early intervention orthopedic care, including osteoarthritis (OA) pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product line includes OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic. Its OA Pain Management product consists of Monovisc and Orthovisc, Cingal, and Hyvisc. Its Joint Preservation and Restoration consist of regenerative solutions, sports medicine, and Arthrosurface joint solutions. Monovisc and Orthovisc are single and multi-injection, HA-based Visco supplement products, Cingal, and Hyvis. Its Non-Orthopedic products consists of HA-based products that are marketed principally for non-orthopedic applications.